Therapeutic potential of mushrooms in preventing and ameliorating hypertension

Trends in Food Science and Technology

Volumn 39, Issue 2, 2014, Pages 104-115

  Mohamed Yahaya, Noor Fazila ^a   Rahman, Mohammad Azizur ^a,b   Abdullah, Noorlidah ^a  

^a UNIVERSITY OF MALAYA   (Malaysia)

^b JAHANGIRNAGAR UNIVERSITY   (Bangladesh)

Author keywords

[No Author keywords available]

Indexed keywords

DRUG INTERACTIONS;

ALTERNATIVE AND COMPLEMENTARY MEDICINE; CARDIO-VASCULAR DISEASE; HYPERTENSIVE DRUG; MEDICINAL MUSHROOM; MODE OF ACTION; PATHOPHYSIOLOGY; SIDE EFFECT; THERAPEUTIC POTENTIALS;

FUNGI;

EID: 84908162871     PISSN: 09242244     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.tifs.2014.06.002     Document Type: Review

References (66)

1. Abdulla M.A., Noor S., Wong K.H., Ali H.M. Effect of culinary-medicinal Lion's mane mushroom, Hericium erinaceus (Bull.: Fr.) Pers. (Aphyllophoromycetideae), on ethanol-induced gastric ulcers in rats. International Journal of Medicinal Mushrooms 2008, 10(4):325-330.
2. Abdullah N., Ismail S.M., Aminudin N., Shuib A.S., Lau B.F. Evaluation of selected culinary-medicinal mushrooms for antioxidant and ACE inhibitory activities. Evidence-based Complementary and Alternative Medicine 2012, 10.1155/2012/464238.
3. Alomar M.J. Factors affecting the development of adverse drug reactions. Saudi Pharmaceutical Journal 2014, 22(2):83-94.
4. Amplavar N.T., Gurpreet K., Salmiah M.S., Odhayakumar N. Prevalence of cardiovascular disease risk factors among attendees of the Batu 9, Cheras Health Centre, Selangor, Malaysia. Medical Journal of Malaysia 2010, 65:166-172.
5. Amy L.V. Vital Signs: awareness and treatment of uncontrolled hypertension among adults- United States, 2003-2010. Morbidity and Mortality Weekly Report (MMWR) 2012, 61(35):703-709.
6. Appel L.J. Lifestyle modification as a means to prevent and treat high blood pressure. Journal of the American Society of Nephrology 2003, 14(Suppl. 2):S99-S102.
7. Ariyo A.A., Haan M., Tangen C.M., Rutledge J.C., Cushman M., Bobs A., et al. Depressive symptoms and risks of coronary heart disease and mortality in elderly Americans. Circulation 2000, 102:1773-1779.
8. Awoke A., Awoke T., Alemu S., Megabiaw B. Prevalence and associated factors of hypertension among adults in Gondar, Northwest Ethiopia: a community based cross-sectional study. BMC Cardiovascular Disorders 2012, 12:133-138.
9. Bakris G.L., Frohlich E.D. The evolution of antihypertensive therapy: an overview of four decades of experience. Journal of the American College of Cardiology 1989, 14(7):1595-1608.
10. Bangalore S., Sawhney S., Messerli F.H. Relation of beta-blocker-induced heart rate lowering and cardioprotection in hypertension. Journal of the American College of Cardiology 2008, 52:1482-1489.
11. Bisen P.S., Baghel R.K., Sanodiya B.S., Thakur G.S., Prasad G.B.K.S. Lentinus edodes: a macrofungus with pharmacological activities. Current Medicinal Chemistry 2010, 17:2419-2430.
12. Boh B., Berovic M., Zhang J., Zhi-Bin L. Ganoderma lucidum and its pharmaceutically active compounds. Biotechnology Annual Review 2007, 13:265-301.
13. Brown N.J., Douglas E.V. Angiotensin-converting enzyme inhibitors. Circulation 1998, 97:1411-1420.
14. Büssemaker E., Hillebrand U., Hausberg M., Pavenstädt H., Oberleithner H. Pathogenesis of hypertension: Interactions among sodium, potassium and also aldosterone. American Journal of Kidney Diseases 2010, 55:1111-1120.
15. Chataut J., Adhikari R., Sinha N. Prevalence and risk factors for hypertension in adults living in central development region of Nepal. Kathmandu University Medical Journal 2012, 9(1):13-18.
16. Chihara G. Immunopharmacology of Lentinan, a polysaccharide isolated from Lentinus edodes: its applications as a host defence potentiator. International Journal of Oriental Medicine 1992, 17:57-77.
17. Chobanian A.V., Bakris G.L., Black H.R., Cushman W.C., Green L.A., Izzo J., et al. The seventh report of the joint national committee on prevention, detection, evaluation, and treatment of high blood pressure: the JNC 7 report. The Journal of the American Medical Association 2003, 289(19):2560-2571.
18. Choi H.S., Cho H.Y., Yang H.C., Ra K.S., Suh H.J. Angiotensin I-converting enzyme inhibitor from Grifola frondosa. Food Research International 2001, 34:177-182.
19. Eaker E.D., Sullivan L.M., Kelly-Hayes M., D'Agostino R.B., Benjamin E.J. Marital status, marital strain and risk of coronary heart disease or total mortality: the Framingham off spring study. Psychosomatic Medicine 2007, 69:509-513.
20. Egan B.M., Zhao Y. Different definitions of prevalent hypertension impact: the clinical epidemiology of hypertension and attainment of healthy people goals. The Journal of Clinical Hypertension 2013, 15:154-161.
21. Ezzati M., Lopez A.D., Rodgers A., Hoorn S.V., Murray C.J. Comparative risk assessment collaborating group. Selected major risk factors and global regional burden of disease. Lancet 2002, 360:1347-1360.
22. Fuchs F.D. Diuretics: again the first step in the treatment of most patients with hypertension. Current Controlled Trials in Cardiovascular Medicine 2001, 2:244-248.
23. Fukushima M., Nakano M., Morii Y., Ohashi T., Fujiwara Y., Sonoyama K. Hepatic LDL receptor mRNA in rats is increased by dietary mushroom (Agaricus bisporus) fiber and sugar beet fiber. The Journal of Nutrition 2000, 130(9):2151-2156.
24. Guillamón A., García-Lafuente A., Lozano M., DArrigo M., Rostagno M.A., Villares A., et al. Edible mushrooms: role in the prevention of cardiovascular diseases. Fitoterapia 2010, 81:715-723.
25. Haddy F.J., Vanhoutte P.M., Feletou M. Role of potassium in regulating blood flow and blood pressure. American Journal of Physiology-Regulatory, Integrative and Comparative Physiology 2006, 290(3):R546-R552.
26. Hagiwara S., Takahashi M., Shen Y., Kaihou S., Tomiyama T., Yazawa M., et al. A phytochemical in the edible tamogi-take mushroom (Pleurotus cornupiae), d-Mannitol, inhibits ACE activity and lowers the blood pressure of spontaneously hypertensive rats. Bioscience, Biotechnology and Biochemistry 2005, 69:1603-1605.
27. Hasnat M.A., Pervin M., Lim B.O. Acetylcholinesterase inhibition and invitro and invivo antioxidant activities of Ganoderma lucidum grown on germinated brown rice. Molecules 2013, 18:6663-6678.
28. Hong F., Ming L., Yi S., Zhanxia L., Yongquan W., Chi L. The antihypertensive effect of peptides: a novel alternative to drugs?. Peptides 2008, 29:1062-1071.
29. Hsing-Hsien C., Wen-Chi H., Mei-Ling L. Interactions of Lipid Metabolism and Intestinal Physiology with Tremella fuciformis Berk Edible Mushroom in Rats Fed a High-Cholesterol Diet with or without Nebaciti. Journal of Agricultural and Food Chemistry 2002, 50:7438-7443.
30. Hyoung Lee D., Ho Kim J., Sik Park J., Jun Choi Y., Soo Lee J. Isolation and characterization of a novel angiotensin I-converting enzyme inhibitory peptide derived from the edible mushroom Tricholoma giganteum. Peptides 2004, 25(4):621-627.
31. Jang J.H., Jeong S.C., Kim J.H., Lee Y.H., Ju Y.C., Lee J.S. Characterisation of a new antihypertensive angiotensin I-converting enzyme inhibitory peptide from Pleurotus cornucopiae. Food Chemistry 2011, 127:412-418.
32. Jao C.L., Huang S.L., Hsu K.C. Angiotensin I-converting enzyme inhibitory peptides: Inhibition mode, bioavailability and antihypertensive effects. BioMedicine 2012, 2:130-136.
33. Je J.Y., Park P.J., Kim B., Kim S.K. Antihypertensive activity of chitin derivatives. Biopolymers 2006, 83(3):250-254.
34. Kabir Y., Kimura S., Tamura T. Dietary effect of Ganoderma lucidum mushroom on blood pressure and lipid levels in spontaneously hypertensive rats (SHR). Journal of Nutritional Science and Vitaminology 1988, 34:433-438.
35. Kabir Y., Kimura S. Dietary mushrooms reduce blood pressure in spontaneously hypertensive rats (SHR). Journal of Nutritional Science and Vitaminology 1989, 35:91-94.
36. Kang M.G., Kim Y.H., Zanabaatar B., Kim M.K., Seo G.S., Lee J.S. Characterization of an antihypertensive angiotensin I-converting enzyme inhibitory peptide from the edible mushroom Hypsizygus marmoreus. BioMed Research International 2013, 10.1155/2013/283964.
37. Kearney P.M., Whelton M., Reynolds K., Muntner P., Whelton P.K., He J. Global burden of hypertension: analysis of worldwide data. The Lancet 2005, 365(9455):217-223.
38. Kiyoto M., Saito S., Hattori K., Cho N.S., Hara T., Yagi Y., et al. Inhibitory effects of l-pipecolic acid from the edible mushroom, Sarcodon aspratus on angiotensin-I-converting enzyme. Journal of Wood Science 2008, 54:179-181.
39. Ko D.T., Hebert P.R., Coffey C.S., Curtis J.P., Foody J.M., Sedrakyan A., et al. Adverse effects of β-blocker therapy for patients with heart failure: a quantitative overview of randomized trials. Archives of Internal Medicine 2004, 164(13):1389-1394.
40. Koo K.C., Lee D.H., Kim J.H., Yu H.E., Park J.S., Lee J.S. Production and characterization of antihypertensive angiotensin I-converting enzyme inhibitor from Pholiota adiposa. Journal of Microbiology and Biotechnology 2006, 16:757-763.
41. Kotchen T.A. Historical trends and milestones in hypertension research a model of the process of translational research. Hypertension 2011, 58(4):522-538.
42. Lau C.C., Abdullah N., Shuib A.S., Aminudin N. Proteomic analysis of antihypertensive proteins in edible mushrooms. Journal of Agricultural and Food Chemistry 2012, 60:12341-12348.
43. Lau C.C., Abdullah N., Shuib A.S., Aminudin N. Novel angiotensin I-converting enzyme inhibitory peptides derived from edible mushroom Agaricus bisporus (J.E. Lange) imbach identified by LC-MS/MS. Food Chemistry 2014, 148:396-401.
44. Lawes C.M., Hoom S.V., Rodgers A. Global burden of blood-pressurerelated disease, 2001. Lancet 2008, 371:1513-1518.
45. Lee S.Y., Rhee H.M. Cardiovascular effects of mycelium extract of Ganoderma lucidum: inhibition of sympathetic outflow as a mechanism of its hypotensive action. Chemical and Pharmaceutical Bulletin 1990, 38(5):1359-1365.
46. Martirosyan D.M. The 9th International Conference on "Functional foods and chronic diseases: Science and practice" 2011, University of Nevada, Las Vegas, USA.
47. Malekzadeh M.M., Etemadi A., Kamangar F., Khademi H., Golozar A., Islami F., et al. Prevalence, awareness and risk factors of hypertension in a large cohort of Iranian adult population. Journal of Hypertension 2013, 31(7):1364.
48. Manzi P., Gambelli L., Marconi S., Vivanti V., Pizzoferrato L. Nutrients in edible mushrooms: an inter-species comparative study. Food Chemistry 1999, 65(4):477-482.
49. Manzi P., Marconi S., Aguzzi A., Pizzoferrato L. Commercial mushrooms: nutritional quality and effect of cooking. Food Chemistry 2004, 84(2):201-206.
50. Mittal B.V., Singh A.K. Hypertension in the developing world: challenges and opportunities. American Journal of Kidney Diseases 2010, 55(3):590-598.
51. Morigiwa A., Kitabatake K., Fujimoto Y., Ikekawa N. Angiotensin converting enzyme-inhibitory triterpenes from Ganoderma lucidum. Chemical and Pharmaceutical Bulletin 1986, 34(7):3025-3028.
52. Nishida Y., Takahashi Y., Nakayama T., Asai S. Comparative effect of angiotensin II type 1 receptor blockers and calcium channel blockers on laboratory parameters in hypertensive patients with type 2 diabetes. Cardiovascular Diabetology 2012, 11:53-64.
53. Onusko E. Diagnosing secondary hypertension. American Family Physician 2003, 67(1):67-74.
54. Oparil S., Zaman M.A., Calhoun D.A. Pathogenesis of hypertension. Annals of Internal Medicine 2003, 139(9):761-776.
55. Paterson R.R.M. Ganoderma-A therapeutic fungal biofactory. Phytochemistry 2006, 67(18):1985-2001.
56. Preuss H.G., Echard B., Bagchi D., Perricone N.V. Maitake mushroom extracts ameliorate progressive hypertension and other chronic metabolic perturbations in aging female rats. International Journal of Medical Sciences 2010, 7(4):169-180.
57. Talpur N.A., Echard B.W., Fan A.Y., Jaffari O., Bagchi D., Preuss H.G. Antihypertensive and metabolic effects of whole maitake mushroom powder and its fractions in two rat strains. Molecular and Cellular Biochemistry 2002, 237:129-136.
58. Rashid A.K., Azizah A.M. Prevalence of hypertension among the elderly Malays living in rural Malaysia. Australasian Medical Journal 2011, 4:283-290.
59. Van der Horst I.C.C., Voors A.A., Van Veldhuisen D.J. Treatment of heart failure with ACE inhibitors and beta-blockers. What is next? aldosterone receptor antagonists?. Clinical Research in Cardiology 2007, 96:193-195.
60. Wasser S.P. Medicinal mushrooms as a source of antitumor and immunomodulating polysaccharides. Applied Microbiology and Biotechnology 2002, 60:258-274. 10.1007/s00253-002-1076-7.
61. Wasser S.P. Current findings, future trends, and unsolved problems in studies of medicinal mushrooms. Applied Microbiology and Biotechnology 2011, 89(5):1323-1332.
62. White W.B. Update on the drug treatment of hypertension in patients with cardiovascular disease. The American Journal of Medicine 2005, 118:695-705.
63. Yadav S., Boddula R., Genitta G., Bhatia V., Bansal B., Kongara S., et al. Prevalence and risk factors of pre-hypertension and hypertension in an affluent north Indian population. Indian Journal of Medical Research 2008, 128:712-720.
64. Yoshitomi H., Iwaoka E., Kubo M., Shibata M., Gao M. Beneficial effect of Sparassis crispa on stroke through activation of Akt/eNOS pathway in brain of SHRSP. Journal of Natural Medicines 2011, 6:135-141.
65. Zeng Y., Du J., Pu X., Yang S.-m., Yang T., Jia P. Strategies of functional food for hypertension prevention in China. Journal of Medicinal Plants Research 2011, 5(24):5671-5676.
66. Zhang L., Yang M., Song Y., Sun Z., Peng Y., Qu K., et al. Antihypertensive effect of 3,3,5,5-tetramethyl-4-piperidone, a new compound extracted from Marasmius androsaceus. Journal of Ethnopharmacology 2009, 123:34-39.